Retina

We support a number of retina clinical research studies, including:

  • AZURE – Efficacy and safety of two different aflibercept regimens in subjects with nAMD

For more information about above please contact josephine.awudza@cmft.nhs.uk / afeefa.rasheeth@cmft.nhs.uk or +44 (0)161 701 6205 /2589

  • DRAKO – An observational study to assess the effectiveness of intravitreal aflibercept (Eylea) in routine clinical practice in patients with visual impairment due to diabetic macular oedema (DMO).

For more information about please contact dominic.o’reilly@cmft.nhs.uk or +44 (0)161 276 3559

  • EDNA – Early Detection of Neovascular Age-related macular degeneration (AMD)

For more information about above please contact afeefa.rasheeth@cmft.nhs.uk or +44 (0)161 701 2589

  • Image analysis study – Customised image analysis tools may offer valuable assistance in extracting clinically relevant information from imaging modalities routinely used in Ophthalmology. This may allow distilling additional information not currently discernible in routine interpretation of imaging data.

For more information please contact emma.columbine@cmft.nhs.uk or +44 (0)161 276 3432

  • IRISS – Evaluating patients with diabetic macular oedema (ODM) who are treated with ILUVIEN.

For more information please contact emma.columbine@cmft.nhs.uk or +44 (0)161 276 3432

  • NAEVUS  – Validation of a virtual model of service delivery for choroidal nevomelanocytic lesions

For more information please contact emma.columbine@cmft.nhs.uk or +44 (0)161 276 3432

  • PIMS – A multicentre interventional comparative randomised controlled clinical trial comparing strictly face-down posturing with relaxed seated position on the outcome of surgery for large macular hole.

For more information please contact josephine.awudza@cmft.nhs.uk or +44 (0)161 701 6205

  • SAFARI – A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related maculardegeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg:the SAFARI study

For more information please contact emma.columbine@cmft.nhs.uk or +44 (0)161 276 3432

  • SPECTRI – A Phase III, Multicentre, randomised, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with geographic atrophy secondary to age related macular degeneration.

For more information please contact charlene.hyde@cmft.nhs.uk / monika.cien@cmft.nhs.uk or +44 (0)161 276 5615 / 701 1765